The authors conduct a meta-analysis, showing that the addition of programmed death-1/programmed death ligand-1 (PD-L1) blockade to chemotherapy improves progression-free survival in PD-L1 positive metastatic TNBC patients, also in the intention-to-treat population.
[Critical Reviews in Oncology Hematology]
Sorry, but the selected Zotpress account can't be found.
